Regeneron/Sanofi's sarilumab heading for regulators for RA
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron have reported topline data from three Phase III trials of their novel anti-inflammatory MAb sarilumab in rheumatoid arthritis that will support filings due in the fourth quarter.